Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill aims to speed COVID-19 recovery in early trial

NCT ID NCT07157007

Symptom relief Sponsor: Traws Pharma, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug, ratutrelvir, in adults with mild to moderate COVID-19 who are not in the hospital. About 90 participants will take the drug plus standard care to see if it is safe and helps symptoms go away faster. The goal is to find the right dose for future studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Mar 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Confirmed SARS-CoV-2 infection for 120 h prior to randomization. 2. Initial onset of signs/symptoms attributable to COVID-19 within 5 days prior to randomization. 3. At least one of the symptoms attributable to COVID-19 present within 24 hours prior to the Day 1 with the severity score of 1 or higher according to the following scoring system for the assessment of severity of: Exclusion Criteria: Medical Conditions: 1. History, current need for hospitalization or anticipated need for hospitalization for the medical treatment of COVID-19. 2. Urgent or expected need for nasal high-flow oxygen therapy or positive pressure ventilation, invasive mechanical ventilation or ECMO. 3. Known medical history of active liver disease . 4. Receiving dialysis or history of moderate to severe renal impairment. 5. Compromised immune system. 6. Acute episode of chronic respiratory diseases, including bronchial asthma, chronic obstructive pulmonary disease within 30 days before screening. 7. Suspected or confirmed concurrent active systemic infection.. Prior/Concomitant Therapy: 8. Has received or is expected to receive any dose of a SARS-CoV-2 vaccine within 4 months of screening and during the participation in the study. 9. Concomitant use of any medications or substances that are strong inducers of CYP3A4

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID -19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID -19

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    15 sites in 4 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chang Gung Memorial Hospital, Linkou Branch

    NOT_YET_RECRUITING

    Taoyuan, Taoyuan, 333, Taiwan

  • Chonnam National University Hospital

    NOT_YET_RECRUITING

    Gwangju, Donggu, 61469, South Korea

  • Hallym University Sacred Heart Hospital Gangnam

    NOT_YET_RECRUITING

    Seoul, Seoul, 07441, South Korea

  • Inha University Hospital

    NOT_YET_RECRUITING

    Incheon, Jung-gu, 22332, South Korea

  • Kaohsiung Medical University Hospital

    NOT_YET_RECRUITING

    Kaohsiung City, Kaohsiung, 807, Taiwan

  • Key Health

    RECRUITING

    Sydney, New South Wales, 2000, Australia

  • Momentum Clinical Research Taringa

    RECRUITING

    Brisbane, Queensland, 4068, Australia

  • Novatrial

    RECRUITING

    Charlestown, New South Wales, 2290, Australia

  • Paratus Clinical(Clinical Trials Institute, Torquay)

    NOT_YET_RECRUITING

    Torquay, Victoria, 3228, Australia

  • Research Institute of Virology

    RECRUITING

    Tashkent, Tashkent, 100194, Uzbekistan

  • Taichung Veterans General Hospital

    NOT_YET_RECRUITING

    Taichung, Taichung, 407, Taiwan

  • Taipei Medical University Hospital

    NOT_YET_RECRUITING

    Taipei, Taipei, 110, Taiwan

  • Taoyuan General Hospital

    NOT_YET_RECRUITING

    Taoyuan, Taoyuan, 33004, Taiwan

  • The Catholic University of Korea, Eunpyeong St. Mary's Hospital

    NOT_YET_RECRUITING

    Seoul, Eunpyeong-gu, 07441, South Korea

  • Wonju Severance Christian Hospital

    NOT_YET_RECRUITING

    Wŏnju, Gangwon-do, 26426, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.